Psilocybin Research: A Comprehensive Overview (Podcast)
A conversational audio deep-dive into current psilocybin research — covering clinical outcomes, mystical-type experiences, safety considerations, microdosing models, species identification, and emerging therapeutic applications. Ideal for commutes and curious minds. Based on 8 peer-reviewed studies sourced from Google Scholar.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar. Unfamiliar terms? See the plain-language glossary →
de la Salle, S., Kettner, H., Thibault Lévesque, J., Garel, N., Dames, S., Patchett-Marble, R., Rej, S., Gloeckler, S., Erritzoe, D., Carhart-Harris, R., & Greenway, K. T. (2024). Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Scientific Reports, 14, 15353. https://doi.org/10.1038/s41598-024-66817-0
26 Canadians who received psilocybin therapy through a special-access program reported real, lasting improvements in their mental health. It wasn't a controlled trial, but it's a valuable look at how the treatment works outside the lab.
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 117, 155–160. https://doi.org/10.1016/j.paid.2017.06.004
People who score high on the personality trait 'neuroticism' were more likely to have a difficult or frightening psilocybin experience — a clue that screening and good preparation matter.
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. (2023). Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. International Journal of Mental Health Nursing, 32(4), 1025–1037. https://doi.org/10.1111/inm.13127
Pulling together many interview-based studies, patients describe psilocybin therapy as emotionally powerful and meaningful — with the bond with the therapist and the 'integration' work afterward mattering as much as the drug itself.
Bradshaw, A. J., Backman, T. A., Ramírez-Cruz, V., Forrister, D. L., Winter, J. M., Guzmán-Dávalos, L., Guzmán-Dávalos, L., Furci, G., Stamets, P., & Dentinger, B. T. M. (2022). DNA authentication and chemical analysis of Psilocybe mushrooms reveal widespread misdeterminations in fungaria and inconsistencies in metabolites. Applied and Environmental Microbiology, 88(24), e01498-22. https://doi.org/10.1128/aem.01498-22
When scientists DNA-tested museum mushroom specimens, many were mislabeled and their psilocybin levels varied wildly — a reminder you can't judge a Psilocybe by its looks, which matters for research quality.
Kurzbaum, E., Páleníček, T., Sharchaton, A., Azerrad, S., & Dekel, Y. (2025). Exploring Psilocybe cubensis strains: Cultivation techniques, psychoactive compounds, genetics and research gaps. Journal of Fungi, 11(2), Article 99. https://doi.org/10.3390/jof11020099
A big-picture review of how Psilocybe cubensis is grown, the active compounds it makes, and the genetics behind them — and how much still isn't standardized from one strain to the next.
Chopra, H., Furnish, T., Verduzco-Gutierrez, M., Jevotovsky, D. S., & Castellanos, J. (2024). Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. Clinical Case Reports, 12, e8791. https://doi.org/10.1002/ccr3.8791
One patient with long-COVID fatigue and brain fog improved after psilocybin and MDMA therapy. A single case can't prove cause and effect, but it opens a question worth studying.
Cohen, J., Sulimani, L., Procaccia, S., Lerenthal, Y., Milay, L., Taran, I., Shapira, A., & Meiri, D. (2025). Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters. Scientific Reports, 15(1), Article 13822. https://doi.org/10.1038/s41598-025-97710-z
Testing 42 mushroom strains showed their active-compound levels differ a lot, even within the same species — strong evidence that 'standardized' doses need careful lab measurement.
Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2022). Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. Journal of Psychopharmacology, 37(1), 49–60. https://doi.org/10.1177/02698811221131997
In a survey of 541 people with bipolar disorder who'd used psilocybin, most reported benefits — but a meaningful minority had manic episodes, so bipolar disorder calls for real caution.
James, E., Robertshaw, T. L., Hoskins, M., & Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. Human Psychopharmacology: Clinical and Experimental, 35(5), e2742. https://doi.org/10.1002/hup.2742
The intensity of the 'mystical' part of a psilocybin session seems to predict how much lasting benefit people get — a sign the experience itself is part of how the therapy works.
Hughes, J., Stuart-Bennett, J., Dunning, M., & Farrimond, H. (2025). Towards a dynamic processual model of psychedelic microdosing. International Journal of Drug Policy, 136, 104691. https://doi.org/10.1016/j.drugpo.2024.104691
In-depth interviews show psilocybin microdosing isn't one fixed thing — the effects shift over time and vary a lot from person to person, pushing back on the idea that it reliably boosts performance.
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. https://doi.org/10.1177/0269881116662634
In a survey of people who had a 'bad trip' on psilocybin mushrooms, most still rated the difficult experience as meaningful afterward — but some reported lasting harm, so these experiences cut both ways.
Nicholas, C. R., Henriquez, K. M., Gassman, M. C., Cooper, K. M., Muller, D., Hetzel, S., Brown, R. T., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018). High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology, 32(7), 770–778. https://doi.org/10.1177/0269881118780713
Testing 5–30 mg doses in healthy volunteers, higher psilocybin doses produced stronger 'mystical' experiences with no serious heart or safety problems — the data used to set doses in later trials.
Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948. https://doi.org/10.3390/molecules26102948
A clear overview of psilocybin as a possible treatment — how it acts in the brain and what trials show for depression, anxiety, addiction, and end-of-life distress.
COMPASS Pathways, Ltd. (2019). Clinical Protocol COMP 001: The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD) [Clinical trial protocol]. ClinicalTrials.gov Identifier: NCT03775200.
The blueprint for the largest psilocybin-for-depression program — it set the doses and methods that later trials followed, but it's a plan, not results.
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7, 13187. https://doi.org/10.1038/s41598-017-13282-7
Brain scans of 20 people with hard-to-treat depression showed psilocybin therapy calmed an overactive 'self-focus' network and increased emotional response — changes that tracked with feeling less depressed.
Shao, L. X., Liao, C., Bhatt, D. L., & Bhatt, D. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 109(16), 2535–2544. https://doi.org/10.1016/j.neuron.2021.06.008
In mice, a single dose of psilocybin quickly grew new connections between brain cells and undid stress-related damage — a strong clue to how it may work, though not yet shown this way in people.
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
In a trial of 24 adults with depression, two psilocybin sessions produced fast, large improvements — 71% responded and over half were in remission a month later — though the study was small.
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
In a careful head-to-head trial, two psilocybin sessions worked about as well as six weeks of a standard antidepressant — and beat it on several secondary measures — though the single main score wasn't a clear-cut win.
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357–364. https://doi.org/10.1080/1355621021000005937
An early, foundational review of what the body does with psilocybin — how it's converted to its active form, how long it lasts, and how it acts on serotonin receptors.
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–292. https://doi.org/10.1007/s00213-006-0457-5
The landmark study that restarted modern psychedelic research: most volunteers rated a high-dose psilocybin session among the most meaningful experiences of their lives, with positive changes still there two months later.